<?xml version="1.0" encoding="UTF-8"?>
<p id="p0160">The short term anti-coagulant, antiviral and antibacterial drug Nafamostat mesylate inhibits Spike protein induced membrane fusion in MERS-CoV and also researchers suggested that using Nafamostat alone or with combination of antiviral drugs could be a safe approach in treating COVID-19 [
 <xref rid="bb0600" ref-type="bibr">120</xref>,
 <xref rid="bb0605" ref-type="bibr">121</xref>].
</p>
